interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Dexamethasone; Tobramycin

Generic competition · all medicines · read 12 November 2026

Is there a generic of Dexamethasone; Tobramycin, and who makes it?

Dexamethasone; Tobramycin appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 11.2 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Dexamethasone; Tobramycin2 dosage-form groups in the Orange Book
2generic makers listed
  1. Dexamethasone; Tobramycin appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 11.2 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Suspension/Drops, Ophthalmic

One to three generic makers listed

Brand listed as marketed: Tobradex and Tobradex St. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 27 October 1999.

198519901995200020052010201520202025203002brand 1988Bausch And Lomb Inc, first approval 27 October 1999Padagis Us Llc, first approval 11 February 2022data datePatent 8101582 listed to expire 19 December 2027Patent 8450287 listed to expire 19 December 2027Patent 7795316 listed to expire 3 August 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Bausch And Lomb Inc27 October 19991
Padagis Us Llc11 February 20221

Patents and exclusivities still listed

  • 19 December 2027Patent 8101582 drug product
  • 19 December 2027Patent 8450287 drug product
  • 3 August 2028Patent 7795316 drug product

Ointment, Ophthalmic

Brand listed, no generic listed as marketed

Brand listed as marketed: Tobradex. No generic is listed as marketed.

198519901995200020052010201520202025203001brand 1988data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.